The Systemic Immune-Inflammation Index in Patients With Metastatic RCC Treated With First-Line TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Impact of the Systemic Immune-Inflammation Index for the Prediction of Prognosis and Modification of the Risk Model in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors
Can Urol Assoc J 2020 Jun 05;[EPub Ahead of Print], J Teishima, S Inoue, T Hayashi, A Matsubara, K Mita, Y Hasegawa, M Kato, M Kajiwara, M Shigeta, S Maruyama, H Moriyama, S FujiwaraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.